Analysis of programmed death-ligand 1 expression in primary normal human dermal fibroblasts after DNA damage

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• Programmed cell death-1 (PD-1) and its ligand PD-L1 are crucial regulators of immune responses.
• Anti-PD-1 therapy offers significant clinical benefits in cancer treatment.
• Previous research indicated DNA double-strand breaks (DSBs) can enhance PD-L1 expression in cancer cells.

Purpose of the Study:

• To investigate PD-L1 expression in normal human dermal fibroblasts (NHDFs) following DNA damage.
• To determine if DNA damage signaling is sufficient to upregulate PD-L1 in non-cancerous cells.

Main Methods:

• NHDFs were exposed to ionizing radiation (IR) and other DNA-damaging agents (camptothecin, etoposide).
• PD-L1 expression, IRF1 and STAT1 phosphorylation were assessed post-treatment.
• Cells were also treated with interferon-gamma (IFNγ) and a histone deacetylase inhibitor (HDACi).

Main Results:

• Ionizing radiation did not upregulate PD-L1, IRF1, or STAT1 phosphorylation in NHDFs.
• Interferon-gamma treatment increased PD-L1, IRF1, and STAT1 phosphorylation.
• Other DNA-damaging agents also failed to induce PD-L1 upregulation.
• HDACi treatment upregulated PD-L1 independently of DNA damage, but IR-induced upregulation was not observed.

Conclusions:

• DNA damage signaling alone is insufficient to upregulate PD-L1 in normal human dermal fibroblasts.
• Interferon-gamma is a potent inducer of PD-L1 in NHDFs.
• The cellular context (cancerous vs. normal) influences PD-L1 response to DNA damage.